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REVIEWCell-Based Therapies for Osteonecrosis of the Femoral
Head
Kevin B. Jones,1,3 Tara Seshadri,2,3 Roselynn Krantz,2 Armand Keating,2,3 Peter C. Ferguson1,3
Osteonecrosis of the femoral head is a disabling condition and a known complication of hematopoietic cell
transplants (HCT). It is characterized by empty lacunae in the osseous matrix and necrotic marrow elements.
The most important risk factor in HCTrecipients is steroid exposure, frequently in the context of graft-ver-
sus-host disease. Current treatment is surgical, and involves decompression of the affected area and the use
of bone grafts or hip arthroplasty. Cellular-based therapies are now under investigation, and can be used in
addition to, or instead of, invasive surgery. This review presents an overview of osteonecrosis with particular
emphasis on HCT recipients and introduces the role of cell therapy, especially with mesenchymal stromal
cells, as a promising new treatment.
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Osteonecrosis of the femoral head is a common
disorder, with 15,000-20,000 new cases estimated to
occur each year in the United States. In North Amer-
ica, osteonecrosis leads to approximately 5% to 18%
percent of the more than 500,000 total hip arthoplas-
ties performed annually. In many Asian countries,
where there is a greater prevalence, this disorder ac-
counts for a majority of hip arthoplasties performed
each year. With progression of the disease to femoral
head collapse and symptomatic hip arthritis, a total
joint arthroplasty is often required, but the percentage
of good to excellent results for hip replacement is not
as high in patients with osteonecrosis as it is in other
patient populations.
There are characteristic pathologic features of os-
teonecrosis in this anatomic location. Nonetheless, the
pathophysiology remains poorly understood. Al-
though a number of different etiologies have been
identified, the clinical presentation results from ele-
ments of the final common pathway of ischemia, oste-
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doi:10.1016/j.bbmt.2008.06.017ocyte necrosis, inadequate repair, loss of structural
integrity of the subchondral trabecuale, and subchon-
dral collapse.
A number of risk factors are well characterized,
with steroid exposure most prominent among them.
However, some patients with osteonecrosis of the fem-
oral head have no appreciable risk factors. Osteonecro-
sis primarily afflicts individuals in their third, fourth,
and fifth decades, who then usually require multiple
surgical procedures during their lifetime. Identifica-
tion of the most effective, population-specific, and
joint-conserving procedures are essential in the reduc-
tion of morbidity and burden of illness.
Definition
As a pathologic entity [1,2], osteonecrosis is de-
fined by the presence of osseous matrix bearing empty
lacunae, the spaces normally populated by living oste-
ocytes. Also necrotic are the marrow elements that
would otherwise fill the interstices of the trabecular
bone. In the femoral head specifically, this region of
necrotic, acellular bone tissue, called the sequestrum,
is surrounded by reparative tissues, including a sweep-
ing front of revascularization and bone formation. Un-
fortunately, this healing process, named creeping
substitution [3], is rarely capable of returning struc-
tural stability to the femoral head prior to progression
to mechanical failure in the form of subchondral
collapse [4].
Clinically, patients with osteonecrosis of the femo-
ral head first present for medical attention with hip
pain. Radiographs reveal few or no findings early in
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has made earlier diagnosis possible. A patient’s disease
is characterized by imaging findings that display both
the extent of involved tissue and the stage of structural
collapse [5,6]. Imaging systems have been developed to
facilitate and standardize description of the progres-
sion of the disorder. Treatments are therefore tailored
to the stage of disease and vary widely. Without inter-
vention, most patients eventually have sufficient pro-
gression of disease [4] that hip arthroplasty becomes
the only definitive option. Because many young pa-
tients are affected and even the good outcomes of
such arthroplasties are insufficiently durable, much at-
tention is focused on developing effective treatments
of the early stages of disease to prevent femoral head
collapse, which invariably leads to secondary arthritis.
Nonetheless, no current method of treatment is con-
sistently effective, and each has drawbacks, driving
a search for improved methods.
Associated Risk Factors
The 2most common exposures associated with the
development of osteonecrosis are use of corticoste-
roids [7] and excessive ingestion of alcohol [8]. The
term avascular necrosis—falling out of favor recently,
but used for decades to describe the condition—relates
more directly to other known risk factors, each associ-
ated with varied intravascular or extravascular means
of blood supply disruption to the femoral head. These
include traumatic hip dislocation, displaced femoral
neck fracture, vasculitis, Caisson’s disease, and sickle
cell anemia. Infection with and treatments for the hu-
man immunodeficiency virus, chronic renal disease,
and certain chemotherapeutic regimens are also con-
sidered risk factors. For some patients, no specific
risk factor is identified.
The complexities inherent to an understanding of
the pathophysiology of osteonecrosis of the femoral
head are well illustrated in the study of the high inci-
dence of osteonecrosis following hematopoietic cell
transplants (HCT). Although this association has
been well recognized for 20 years, it is far from being
well understood [9]. The prevalence appears signifi-
cantly higher after allogeneic HCT than autologous
HCT [10]. Cumulative incidence of this complication
generally ranges from 5% to 20% at 5 to 15 years after
HCT [11-14], with the mean time from HCT to os-
teonecrosis development being 12 to 15 months
[11,12,15].
An obvious focus in understanding this setting for
osteonecrosis of the femoral head has been the use of
corticosteroids for the treatment of related acute or
chronic graft-versus-host disease (aGVHD ,cGVHD).
Although corticosteroid use in this circumstance has
consistently been demonstrated to be an important
risk factor for osteonecrosis formation [13,16-18],the relative importance of corticosteroid use versus
the inflammatory changes in the microvasculaure
from the GVHD itself are difficult to tease out. Most
of the data available from the literature are retrospec-
tive and rarely include corticosteroid dosing. A large
retrospective study by Socie et al. [13] analyzed risk
factors for the development of osteonecrosis following
allogeneic hematopoietic stem cell transplant in 4388
patients. They reported odds ratios of 3.73 and 3.52
for aGVHD and cGVHD, respectively. Severity of
GVHD also correlated with a higher frequency of os-
teonecrosis. Unfortunately, the details of corticoste-
roid dosing were not analyzed, leaving as many
questions as answers. In a smaller, but prospective
study, Schulte et al. [14] followed 255 patients for a pe-
riod of 4 years after allogeneic HCT for various hema-
tologic diseases. Chronic GVHD was associated with
severe osteonecrosis. However, steroid intake ap-
peared to correlate better and remained significantly
predictive of the development of osteonecrosis in the
multivariate analysis. Another prospective study on
553 patients withmultiple myeloma undergoing autol-
ogous HCT found a direct relationship between cu-
mulative dexamethasone exposure and osteonecrosis
incidence [19].
Subgroup risk factors of age and gender for the de-
velopment of osteonecrosis following HCT have been
inconsistently reported in the literature. Some studies
reported that younger age at transplant appeared to in-
crease the risk [14,20], whereas others found older age
at transplant [18,21] and older age per se were more
significant [11,13]. An early study initially demon-
strated that male gender was associated with an in-
creased the risk of osteonecrosis [12]; however, later
studies have demonstrated a higher incidence in fe-
males [14] and others have not demonstrated any sig-
nificance of gender at all [11,22].
The impact of the HCT-prompting underlying
disease on the development of osteonecrosis has also
been explored. One study reported that the incidence
of osteonecrosis was significantly higher in patients
who underwent allogeneic HCT for diseases other
than chronic myeloid leukemia (CML) [14]. Here,
no cases of severe hip osteonecrosis occurred in the
152 patients with CML versus a 4-year cumulative in-
cidence of 20% in patients with other hematologic dis-
eases (P\ .0001). In contrast, other investigators have
demonstrated relatively similar incidences of osteo-
necrosis in their CML and acute myeloid leukemia
(AML) patients at approximately 10% and 7%, respec-
tively [17]. Another long-term follow-up study of
CML patients undergoing allogeneic HCT found
a 12% incidence of osteonecrosis at 15 years post-
HCT with those patients experiencing cGVHD dem-
onstrating increased risk [23]. As with age and gender,
underlying disease as an independent risk factor is far
from sorted out.
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ute to the development of osteonecrosis of the femoral
head. In an analysis of 4 studies that compared the
conditioning regimens busulfan-cyclophosphamide
and TBI-cyclophosphamide in patients with AML
and CML [17], patients with CML who received
TBI-based conditioning had a higher incidence of
osteonecrosis (10%) compared to those who received
bulsulfan-cyclophosphamide (3%). However, the con-
tribution of TBI to the development of osteonecrosis
was not significant in the multivariate analysis. Fur-
ther, no significant difference was noted with the
AML cohort. Two other studies have demonstrated
a higher risk of osteonecrosis in TBI recipients on uni-
variate analysis [13,24], but again, significance was not
reached after adjusting for confounding factors [13].
As an illustration of the difficulties intrinsic to un-
derstanding osteonecrosis of the femoral head in gen-
eral, the study of its development following HCT has
raised, but not settled the potential contributions of
GVHD, corticosteroid treatment for GVHD, under-
lying hematologic malignancy or other disease, TBI,
age, and gender. As is the case with other settings of os-
teonecrosis, the use of corticosteroids following HCT
is the best documented risk factor. Even if risk factor
associations are difficult, however, their study is far
ahead of the study of pathogenesis of osteonecrosis
of the femoral head.
Theories on Pathogenesis
Although the death of osteocytes and marrow ele-
ments in a region of limited blood supply can be read-
ily explained by traumatic disruption of all vascular
routes in and out of the region [25], understanding
how exposure to steroids or excessive ethanol leads
to an identical pathology has been less forthcoming.
Decades of research have led to the development of
a number of theories, including venous occlusion
[25], vessel wall injury [26], fat embolism [27], micro-
fracture from trabecular insufficiency, intraosseous hy-
pertension [28], intraosseous hemorrhage [29],
vasculitis [30], and intravascular coagulation [31],
none of which has been proven inmore than aminority
of cases or modeled to effectively recapitulate the pa-
thology in an animal model.
A major challenge to understanding osteonecrosis
of the femoral head is the variability in its develop-
ment. Even complete traumatic disruption of femoral
head perfusion does not consistently lead to osteonec-
rosis. There is certainly a time element that figures
prominently in the course of the disease, where healing
of an insulted femoral head races mechanical failure.
Variation in the time course of healing in different pa-
tients may generate the recognized clinical entity more
than the initial insult itself. As noted above, the 2 most
common risk factors for osteonecrosis of the femoralhead are systemic exposures that generally alter mus-
culoskeletal healing potential. Further, local (proximal
femur away from the sequestrum) [32] and even re-
gional (ilium) [33] deficits in the osteogenic potential
of available mesenchymal cell populations have been
demonstrated in patients with osteonecrosis from var-
ied etiologies. These suggest that a global or regional
disablement of healing potential may yield the condi-
tions that generate clinically apparent osteonecrosis.
This is corroborated by the demonstration that expo-
sure to corticosteroids, which increases an individual’s
risk for osteonecrosis of the femoral head, also shunts
mesenchymal progenitor cells toward adipogenesis
and away from osteogenesis [34,35].
Traditional Treatment Paradigms
Total hip arthroplasty remains the only definitive
treatment of osteonecrosis of the femoral head, in
that the presumably diseased tissues are completely re-
sected, prior to reconstruction with artificial implants.
Although the bulk of disease is irrevocably removed,
the durability of the reconstructive option is usually
insufficient for the young population affected by
osteonecrosis. Further, there is the suspicion that
long-term results of total hip arthroplasty in the spe-
cific setting of osteonecrosis of the femoral head are
compromised by more than just the elevated longevity
and activity levels of the young patients affected
[36,37]. It is suspected that other, yet unexplored
aspects of the biology of osteonecrosis may affect the
interface of the surrounding bones with the implants.
A regional or even global deficit in osteogenic reserves
is suggested. For these reasons, arthroplasty is an un-
desirable last resort in most patients with osteonecro-
sis. Most other available treatments aim at postponing,
if not preventing the structural collapse of the femoral
head, which nearly always results in the need for
arthroplasty.
Pharmacotherapy
A number of drugs have been suggested for use in
treating osteonecrosis, but have never gained the mo-
mentum or the evidence required for widespread use.
These would include certain antihypertensive medica-
tions, lipid lowering agents, and anticoagulants.
More recently proposed and definitely gaining
momentum has been the use of bisphonates [38-41].
These ignore the pathophysiology of the disease pro-
cess, but directly tackle the disabling result of that
pathophysiology—mechanical failure of the osteone-
crotic femoral head. Although bisphosphonates show
promise as effective short-term deferment pharmaco-
therapies, the duration of effectiveness against collapse
and the long-term risks of the use of bisphosphonates
in the young adult population have not been fully
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as temporizing treatments only.
Core decompression
The most commonly implemented treatment for
osteonecrosis of the femoral head is core decompres-
sion. Originally described by Ficat and Arlet [42],
opening the osteonecrotic zone of the femoral head
with trephines, drills, or reamers introduced laterally
via the trochanter and femoral neck is readily per-
formed by most orthopedic surgeons and carries few
serious risks beyond progression of the disease itself.
A systematic review [4] of 24 studies including 1206
patients noted clinical success in 63% of precollapse
patients and 23% progression to total hip arthoplasty
by a mean follow-up of 30 months. As the decompres-
sion naturally leaves a structural defect, many methods
of filling the trephine’s track have been utilized, in-
cluding varied bone grafts, bone graft substitutes,
and even metallic implants [43].
Bone grafting
The original idea behind the use of bone grafting
after drilling of osteonecrosis was to reconstruct the
structural integrity of the bone. Stuctural grafts were
originally made popular by Phemister [44]. Although
early results of these techniques seemed promising ini-
tially [45], longer follow-up showed only 25% success
at a mean of 16 years [46]. Nonetheless, structural
bone grafts applied via a number of anatomic ap-
proaches continue to be utilized by some treating sur-
geons [47-49].
In the middle of the 1970s, it began to be proposed
that the biologic activity of bone grafts might be more
critical than the structural stability alone [50]. High
failure rates led to the consideration of varied forms
of vascularized bone tissue transfers. The technique
that reported the strongest results was the use of
a free, vascularized fibular autograft [51]. Unfortu-
nately, this technique is arduous, expensive, and not
widely reproducible at many medical centers.
Cell-Based Therapies
A convergence of 3 different perspectives on the
treatment of osteonecrosis has resulted in exploration
of cell-based therapies. First, patient and surgeon-
driven emphasis onminimizing the invasiveness of sur-
gical interventions has led many to question both the
complexity and donor site morbidity of vascularized
free fibular transfers and the pain associated with iliac
crest-derived autografts. Second, the unassailable rec-
ognition that the time course to healing may critically
differentiate between an ultimately preserved and an
ultimately collapsed femoral head has emphasized
the importance of potential methods to enable the
healing process. Finally, the contribution of a compro-mised healing capacity as a pathologic feature of osteo-
necrosis has been recognized, urging the need to
introduce healing potential exogenously. Recognizing
the potential role of a mesenchymal cell deficit in the
evolution of the disease, Gangji et al. [52] undertook
a small prospective cohort study to assess the safety
and efficacy of the transplant of autologous bone mar-
row mononuclear cells into the necrotic lesion of the
femoral head in patients with early stage (I and II) os-
teonecrosis. Overall significant decreases in level of
pain and joint symptoms and a significant reduction
in the ratio of volume of the necrotic lesion to volume
of femoral head where observed. Five of the 8 control
group members deteriorated to stage III disease,
whereas only 1 of the 10 transplanted patients pro-
gressed to this stage. No significant treatment-related
adverse effects were noted in either group.
As the use of cellular grafts simply arose as an ex-
tension of bone grafting, the bulk of experimentation
has been without preclinical background. This is partly
because of the paucity of good animal models of the
full process of osteonecrosis and subsequent collapse.
The use of an iliac crest bone marrow aspirate rather
than a surgically obtained iliac crest bone graft was ini-
tially proposed in 1990 as an appropriate, biologically
active filler for the defect left after decompression [53].
A few reports have followed, including results from 2
formal series [52-58]. Hernigou and Beaujean [54] re-
ported .5-year follow-up results from 116 patients
with 189 affected hips treated by core decompression
and implantation of the mononuclear cell component
from centrifugation of aspirated iliac crest bone mar-
row. Only 9 of 145 precollapse patients went on to
need hip arthoplasty. Twenty-five of 44 collapsed fem-
oral heads needed arthoplasty by the end of follow-up.
Further, a dose-response correlation was noted be-
tween the clinical success rate and the separately mea-
sured concentration of fibroblast colony forming units
(F-CFU) implanted. Of note, the number of F-CFU
obtained from patients who developed osteonecrosis
secondary to alcohol or corticosteroid use was lower
than the number of F-CFU found in patients who
had a different underlying etiology. This was inter-
preted as evidence that corticosteroids and alcohol
may be specifically toxic to these progenitor cells. An-
other article [58] reported on 3 patients treated with
core decompression, free vascularized fibula, and au-
tologous mesenchymal stem cells cultured in beta-tri-
calcium phosphate ceramic. Few conclusions can be
drawn from the small number in this latter study, but
it demonstrates that new techniques continue to be
attempted.
Preclinical models for testing are somewhat scarce,
as only 2 have been described that proceed to full col-
lapse of the femoral head [59-61]. One of these has
been tested with human bone morphogenic protein 2
gene-transduced bone marrow-derived mesenchymal
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ceramic. Results were promising, in that collapse could
be thwarted and healing complete.
CONCLUSIONS
Although the etiology of osteonecrosis of the fem-
oral head remains elusive, associated local deficits in
the regenerative potential of autologous stem cells
have been noted. This has long raised awareness of
the need to alter the biologic capacity for repair. Al-
though this has traditionally been addressed with vas-
cularized and nonvascularized bone grafts, the
complexities, complications, and failure rates of these
procedures drive the continued search for less invasive,
more effective treatments. The use of bone marrow-
derived mesenchymal stromal cells (MSCs) as an ad-
junct to core decompression has shown promising
results in 1 large series, and statistically significant
improvements in outcomes in a small pilot randomized
control trial.
On theoretical grounds alone, there are several
compelling reasons to consider the MSC population
[62]—whether derived from the bone marrow or
from other sources—as particularly suitable for the re-
generation of osteonecrotic bone. First, in vitro as well
as in vivo data suggest that MSCs are capable of under-
going osteogenic differentiation and mediating bone
mineralization [63,64]. Second, their role in improving
the hemodynamic function of injured myocardium in
animal models has been attributed to the elaboration
of paracrine factors such as vascular endothelial
growth factor that lead to neovascularization [65]. Ad-
ditionally, it is possible that the regenerative potential
of MSCs is influenced by remodelling of the extracel-
lular matrix [66], a conceivably important factor in re-
versing the pathologic processes that initiate
osteonecrosis.
Nonetheless, autologous bone marrow-derived
MSCs in patients with osteonecrosis of the femoral
head show decreased regenerative potential, perhaps
as a result of exposure to the same (bone marrow mod-
ifying/toxic) pharmacologic agents (ie, steroids and al-
cohol) or as a result of risk-elevating comorbid
illnesses. Allogeneic MSCs from normal donors would
be expected to exert superior regenerative properties,
thereby overcoming the limitations of autologous
cells. Moreover, there is accumulating evidence that
MSCs are nonimmunogenic and do not require HLA
matching with the recipient to exert an effect [63].
Sources of such cells are plentiful and are not restricted
to the bone marrow but include adipose tissue and the
umbilical cord [67].
Given the morbidity associated with osteonecrosis
of the femoral head, early phase studies with MSCs
should be encouraged.ACKNOWLEDGMENTS
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